Carisoprodol

Routes
Oral (PO)
Half-Life (t½)
PO: 8h
Formula
C12H24N2O4
Molecular Weight
260.33 g/mol
PubChem CID
2576
Aliases
Soma

Pharmacological Mechanism

Skeletal muscle relaxant — pro-drug largely converted to meprobamate (a Schedule IV barbiturate-like sedative). Schedule IV; abuse potential + physical dependence are concerns. Outpatient acute musculoskeletal pain only short-term.

Half-Life & Elimination Curve (PO: 8h)

100%50%25%12.5%0%0h0×t½8h1×t½16h2×t½24h3×t½32h4×t½40h5×t½0×t½ (0h): 100% remaining (~1.62 mg/L)1×t½ (8h): 50% remaining (~0.811 mg/L)2×t½ (16h): 25% remaining (~0.405 mg/L)3×t½ (24h): 12.5% remaining (~0.203 mg/L)4×t½ (32h): 6.3% remaining (~0.101 mg/L)5×t½ (40h): 3.1% remaining (~50.7 µg/L)
Plasma (PO)t½ Decay (8h)
  • 0×t½0h100% (1.62 mg/L)
  • 1×t½8h50% (0.811 mg/L)
  • 2×t½16h25% (0.405 mg/L)
  • 3×t½24h12.5% (0.203 mg/L)
  • 4×t½32h6.3% (0.101 mg/L)
  • 5×t½40h3.1% (50.7 µg/L)
Elimination t½8h (PO)
Rate Constant (ke)0.0866 h⁻¹
Time to Peak (Tmax)2.12h
Est. Peak (Cmax)1.62 mg/L
Clearance (CL)6.67 L/h
97% Washout (5×t½)40h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References